Brokerages Set Haleon plc (LON:HLN) Target Price at GBX 407.83

Haleon plc (LON:HLN) has earned an average recommendation of “Moderate Buy” from the six research firms that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is GBX 407.83.

Several equities analysts recently issued reports on HLN shares. JPMorgan Chase & Co. boosted their price objective on Haleon from GBX 315 to GBX 335 and gave the company an “underweight” rating in a research report on Wednesday, November 26th. Deutsche Bank Aktiengesellschaft decreased their price objective on Haleon from GBX 340 to GBX 335 and set a “buy” rating for the company in a report on Thursday, January 22nd. Finally, Jefferies Financial Group reissued a “buy” rating and issued a GBX 450 price objective on shares of Haleon in a report on Wednesday, January 21st.

Haleon Price Performance

Haleon stock opened at GBX 393.20 on Friday. Haleon has a 1 year low of GBX 325.10 and a 1 year high of GBX 419.50. The company has a current ratio of 0.87, a quick ratio of 0.93 and a debt-to-equity ratio of 53.60. The firm has a market capitalization of £35.02 billion, a P/E ratio of 21.25, a PEG ratio of 1.49 and a beta of 0.25. The business has a 50-day moving average of GBX 385.27 and a 200-day moving average of GBX 367.10.

Haleon (LON:HLN) last posted its earnings results on Thursday, February 26th. The company reported GBX 18.60 earnings per share for the quarter. Haleon had a net margin of 13.81% and a return on equity of 9.40%. On average, equities analysts anticipate that Haleon will post 19.5033282 EPS for the current year.

Haleon Company Profile

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.